Results 21 to 30 of about 4,731,201 (386)

Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

Circulation, 2021
The global obesity epidemic is well established, with increases in obesity prevalence for most countries since the 1980s. Obesity contributes directly to incident cardiovascular risk factors, including dyslipidemia, type 2 diabetes, hypertension, and ...
Tiffany Powell-wiley, P. Poirier, L. Burke, J. Despres, P. Gordon-Larsen, C. Lavie, S. Lear, C. Ndumele, I. Neeland, P. Sanders, M. St-Onge   +10 more
semanticscholar   +1 more source

Correction to: Diagnostic performance of semi-quantitative and quantitative stress CMR perfusion analysis: a meta-analysis

Journal of Cardiovascular Magnetic Resonance, 2018
In the original publication of this article there was an error in Figures 8, 9, 10 and 11. During typesetting the Figures 8, 9, 10 and 11 have been incorrectly swapped.
Journal of Cardiovascular Magnetic Resonance
doaj   +1 more source

Inflammatory residual risk. An emerging target to reduce cardiovascular disease [PDF]

, 2018
Cardiovascular Residual Risk and Cardiovascular ...
Presta, Vivianne, Volpe, Massimo
core   +1 more source

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

New England Journal of Medicine, 2016
BACKGROUND The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.
S. Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R. Poulter, Lasse S Ravn, William M Steinberg, M. Stockner, B. Zinman, R. Bergenstal, J. B. Buse   +14 more
semanticscholar   +1 more source

Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. [PDF]

, 2019
BACKGROUND: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear.
Alver, M. (Maris), Amouyel, P. (Philippe), Bakker, S.J.L. (Stephan), Benjamin, E.J. (Emelia J.), Blankenberg, S. (Stefan), Bobak, M. (Martin), Brambilla, P. (Paolo), Brenner, H. (Hermann), Brunner, F.J. (Fabian J), Costanzo, S. (Simona), Dallongeville, J., de Lemos, J.A. (James A), Dobson, A. (Annette), Donfrancesco, C. (Chiara), Drygas, W. (Wojciech), Dullaart, R.P.F. (Robin P.F.), Dörr, M. (Marcus), Eliasson, M. (Mats), Engström, G., Ferrières, J. (Jean), Giampaoli, S. (Simona), Gianfagna, F. (Francesco), Giles, G. (Graham), Grassi, G. (Guido), Hodge, A. (Allison), Hveem, K. (Kristian), Iacoviello, L. (Licia), Ikram, M.K. (M. Kamran), Ingelsson, M. (Martin), Jorgensen, T. (Torben), Jousilahti, P. (Pekka), Jääskeläinen, T. (Tuija), JöCkel, K.-H. (Karl-Heinz), Kavousi, M. (Maryam), Kee, F. (F.), Klotsche, J. (Jens), Koenig, W. (Wolfgang), Kontto, J. (Jukka), Kuulasmaa, K. (Kari), Lackner, K.J. (Karl), Landmesser, U. (Ulf), Leistner, D.M. (David M), Linneberg, A. (Allan), Lorenz, T. (Thiess), Lyngbakken, M.N. (Magnus N.), Magliano, D.J., Makarova, N. (Nataliya), Malyutina, S., Mathiesen, E.B. (Ellisiv), Meisinger, C. (Christa), Melander, O. (Olle), Metspalu, A. (Andres), Moitry, M. (Marie), Männistö, S. (Satu), Nauck, M. (Matthias), Niiranen, T. (Teemu), Nikitin, Y., Ojeda, F. (Francisco), Omland, T. (Torbjørn), Pajak, A. (Andrzej), Panagiotakos, D.B. (Demosthenes), Peters, A. (Annette), Pitsavos, C. (Christos), Riserus, U. (Ulf), Salomaa, V. (Veikko), Sans, S. (Susana), Schmidt, B. (Börge), Schöttker, B. (Ben), Shaw, J.E., Shea, S. (Steven), Signorini, S. (Stefano), Simons, L.A. (Leon), Söderberg, S. (Stefan), Tamosiunas, A. (Abdonas), Thorand, B. (Barbara), Tunstall-Pedoe, H. (Hugh), Twerenbold, R. (Raphael), Vasan, R.S. (Ramachandran Srini), Veronesi, G. (Giovanni), Völzke, H. (Henry), Waldeyer, C. (Christoph), Wannamethee, S.G. (Goya), Whincup, P.H. (Peter), Wild, P.S. (Philipp), Wilsgaard, T. (Tom), Woodward, M. (Mark), Zeller, T. (Tanja)   +86 more
core   +10 more sources

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

New England Journal of Medicine, 2016
BACKGROUND Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk.
S. Marso, S. Bain, A. Consoli, F. Eliaschewitz, E. Jódar, Lawrence A Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M. Warren, V. Woo, O. Hansen, A. Holst, Jonas Pettersson, T. Vilsbøll   +14 more
semanticscholar   +1 more source

Long‐Term Outcomes of Acute Kidney Injury After Different Types of Cardiac Surgeries: A Population‐Based Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Dialysis‐requiring acute kidney injury (D‐AKI) is a major complication of cardiovascular surgery that results in worse prognosis. However, the incidence and impacts of D‐AKI in different types of cardiac surgeries have not been fully ...
Jia‐Jin Chen, Chih‐Hsiang Chang, Victor Chien‐Chia Wu, Shang‐Hung Chang, Kuo‐Chun Hung, Pao‐Hsien Chu, Shao‐Wei Chen   +6 more
doaj   +1 more source

The Effect of Nutritional Status, Level of Physical Activity and Hemoglobins on Physical Endurance

Juara, 2019
Technological developments have an impact on increased consumption of junk food. On the other hand, the change was also followed by nutritional problems which later became a trigger factor for the increasing prevalence of physical inactivity which had an
Moh Nanang Himawan Kusuma, Muhamad Syafei, Didik Rilastiyo   +2 more
doaj   +1 more source

Out‐of‐Hospital Cardiac Arrests and Wildfire‐Related Particulate Matter During 2015–2017 California Wildfires

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background The natural cycle of large‐scale wildfires is accelerating, increasingly exposing both rural and populous urban areas to wildfire emissions. While respiratory health effects associated with wildfire smoke are well established, cardiovascular ...
Caitlin G. Jones, Ana G. Rappold, Jason Vargo, Wayne E. Cascio, Martin Kharrazi, Bryan McNally, Sumi Hoshiko   +6 more
doaj   +1 more source

Cardiovascular morbidity and mortality after kidney transplantation [PDF]

, 2014
Kidney transplantation is the optimal treatment for patients with end stage renal disease (ESRD) who would otherwise require dialysis. Patients with ESRD are at dramatically increased cardiovascular (CV) risk compared to the general population.
Jardine, Alan G., Mark, Patrick B., Stoumpos, Sokratis   +2 more
core   +1 more source